Transforming Growth Factor-Beta in Osteolytic Breast Cancer Bone Metastases

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

Breast cancers frequently metastasize to the skeleton and cause bone destruction. Tumor cells secrete factors that stimulate osteoclasts. The consequent osteolytic resorption releases active factors from the bone matrix, in particular transforming growth factor-beta (TGF-β). The released factors then stimulate tumor cell signaling, which causes breast cancer cells to make increased amounts of osteolytic factors, such as parathyroid hormone-related protein (PTHrP), interleukin-11 (IL-11), and vascular endothelial growth factor (VEGF). Therefore, tumor cell-bone cell interactions cause a vicious cycle in which tumor cells stimulate bone cells to cause bone destruction. As a consequence, the local microenvironment is enriched with factors that fuel tumor growth in bone. Transforming growth factor-beta is of particular importance because it increases breast cancer production of PTHrP. Parathyroid hormone-related protein then stimulates osteoblasts to express RANK (receptor activator of nuclear factor kappa B) ligand, which in turns enhances osteoclast formation and activity. Breast cancer osteolytic metastasis can be interrupted at four points in the vicious cycle: by neutralizing PTHrP biologic activity, by blocking the TGF-β signaling pathway in the tumor cells, by inhibiting PTHrP gene transcription, and by inhibiting bone resorption.

Original languageEnglish (US)
JournalClinical Orthopaedics and Related Research
Issue number415 SUPPL.
StatePublished - Oct 2003
Externally publishedYes

Fingerprint

Bone Neoplasms
Transforming Growth Factor beta
Parathyroid Hormone-Related Protein
Breast Neoplasms
Neoplasm Metastasis
Bone and Bones
Neoplasms
Osteoclasts
Interleukin-11
RANK Ligand
Parathyroid Neoplasms
Bone Matrix
Bone Development
Bone Resorption
Osteoblasts
Skeleton
Cell Communication
Vascular Endothelial Growth Factor A
Genes

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

@article{13b7c375e81d4550ae45d77984cfa336,
title = "Transforming Growth Factor-Beta in Osteolytic Breast Cancer Bone Metastases",
abstract = "Breast cancers frequently metastasize to the skeleton and cause bone destruction. Tumor cells secrete factors that stimulate osteoclasts. The consequent osteolytic resorption releases active factors from the bone matrix, in particular transforming growth factor-beta (TGF-β). The released factors then stimulate tumor cell signaling, which causes breast cancer cells to make increased amounts of osteolytic factors, such as parathyroid hormone-related protein (PTHrP), interleukin-11 (IL-11), and vascular endothelial growth factor (VEGF). Therefore, tumor cell-bone cell interactions cause a vicious cycle in which tumor cells stimulate bone cells to cause bone destruction. As a consequence, the local microenvironment is enriched with factors that fuel tumor growth in bone. Transforming growth factor-beta is of particular importance because it increases breast cancer production of PTHrP. Parathyroid hormone-related protein then stimulates osteoblasts to express RANK (receptor activator of nuclear factor kappa B) ligand, which in turns enhances osteoclast formation and activity. Breast cancer osteolytic metastasis can be interrupted at four points in the vicious cycle: by neutralizing PTHrP biologic activity, by blocking the TGF-β signaling pathway in the tumor cells, by inhibiting PTHrP gene transcription, and by inhibiting bone resorption.",
author = "Theresa Guise and John Chirgwin",
year = "2003",
month = "10",
language = "English (US)",
journal = "Clinical Orthopaedics and Related Research",
issn = "0009-921X",
publisher = "Springer New York",
number = "415 SUPPL.",

}

TY - JOUR

T1 - Transforming Growth Factor-Beta in Osteolytic Breast Cancer Bone Metastases

AU - Guise, Theresa

AU - Chirgwin, John

PY - 2003/10

Y1 - 2003/10

N2 - Breast cancers frequently metastasize to the skeleton and cause bone destruction. Tumor cells secrete factors that stimulate osteoclasts. The consequent osteolytic resorption releases active factors from the bone matrix, in particular transforming growth factor-beta (TGF-β). The released factors then stimulate tumor cell signaling, which causes breast cancer cells to make increased amounts of osteolytic factors, such as parathyroid hormone-related protein (PTHrP), interleukin-11 (IL-11), and vascular endothelial growth factor (VEGF). Therefore, tumor cell-bone cell interactions cause a vicious cycle in which tumor cells stimulate bone cells to cause bone destruction. As a consequence, the local microenvironment is enriched with factors that fuel tumor growth in bone. Transforming growth factor-beta is of particular importance because it increases breast cancer production of PTHrP. Parathyroid hormone-related protein then stimulates osteoblasts to express RANK (receptor activator of nuclear factor kappa B) ligand, which in turns enhances osteoclast formation and activity. Breast cancer osteolytic metastasis can be interrupted at four points in the vicious cycle: by neutralizing PTHrP biologic activity, by blocking the TGF-β signaling pathway in the tumor cells, by inhibiting PTHrP gene transcription, and by inhibiting bone resorption.

AB - Breast cancers frequently metastasize to the skeleton and cause bone destruction. Tumor cells secrete factors that stimulate osteoclasts. The consequent osteolytic resorption releases active factors from the bone matrix, in particular transforming growth factor-beta (TGF-β). The released factors then stimulate tumor cell signaling, which causes breast cancer cells to make increased amounts of osteolytic factors, such as parathyroid hormone-related protein (PTHrP), interleukin-11 (IL-11), and vascular endothelial growth factor (VEGF). Therefore, tumor cell-bone cell interactions cause a vicious cycle in which tumor cells stimulate bone cells to cause bone destruction. As a consequence, the local microenvironment is enriched with factors that fuel tumor growth in bone. Transforming growth factor-beta is of particular importance because it increases breast cancer production of PTHrP. Parathyroid hormone-related protein then stimulates osteoblasts to express RANK (receptor activator of nuclear factor kappa B) ligand, which in turns enhances osteoclast formation and activity. Breast cancer osteolytic metastasis can be interrupted at four points in the vicious cycle: by neutralizing PTHrP biologic activity, by blocking the TGF-β signaling pathway in the tumor cells, by inhibiting PTHrP gene transcription, and by inhibiting bone resorption.

UR - http://www.scopus.com/inward/record.url?scp=0142250340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142250340&partnerID=8YFLogxK

M3 - Article

JO - Clinical Orthopaedics and Related Research

JF - Clinical Orthopaedics and Related Research

SN - 0009-921X

IS - 415 SUPPL.

ER -